### **Company Overview** Entero Healthcare Solutions Ltd, founded in 2018 by Prabhat Agarwal and Prem Sethi, is one of India’s **leading and fastest-growing healthcare product distributors**, ranked among the **top three by revenue**. The company went public with a successful IPO in **February 2024**, raising ₹1,000 crores to fund inorganic expansion, working capital, and debt repayment. Post-IPO, Entero has accelerated its strategic growth, achieving **₹5,096 crore in revenue in FY25 (FY2024–25)**—a 30% year-on-year increase—significantly outpacing the Indian Pharmaceutical Market (IPM) growth of 8%. With a mission to build **India’s most comprehensive, digitally integrated, and organized healthcare distribution platform**, Entero combines **demand generation and demand fulfillment** into a full-stack, technology-driven ecosystem that serves pharmaceutical companies, hospitals, retail pharmacies, and consumers. --- ### **Core Business Model: Full-Stack, Integrated Distribution Platform** Entero operates a **differentiated, end-to-end model** that sets it apart from traditional distributors or logistics providers: - **Demand Fulfilment**: Handles pan-India **distribution of pharmaceuticals, OTC products, medical devices, nutraceuticals, surgical & hygiene consumables, and specialty products**. Services include import management, central warehousing, redistribution, and last-mile delivery. - **Demand Generation**: Deploys its **trained medical representatives and marketing teams** to promote brands to doctors, design **channel and go-to-market strategies**, and enhance **market access and patient reach** for manufacturers. This **dual-service model** creates significant operational synergies across its extensive network of pharmacies, hospitals, and manufacturers. --- ### **Key Strategic Partnerships** Entero acts as a **strategic growth partner** for global and domestic manufacturers, providing integrated commercial and supply chain solutions: - **Roche**: Long-standing collaboration for **marketing, promotion, and distribution of four nephrology drugs** in India since 2020. - **Abbott**: Partnership for pan-India reach in **specialty segments** such as CVD and Neurology. - **Servier India**: Distribution of **anti-hypertensive products**. - **Biodis Pharmaceuticals**: Partnership for **4DryField surgical kits**. --- ### **Market Position & Scale (Nov 2025)** Entero boasts one of the **widest distribution footprints in India**: - **Geographic Reach**: - Covers **490 districts across 20 states and 4 union territories**. - Serves **47 cities** via **113 strategically located warehouses** with **610,169 sq. ft. of storage capacity**. - **Customer Base**: - Supplies over **85,300 retail pharmacies** and **2,800+ hospitals** (Q2 FY26: 73,900 pharmacies, 2,400 hospitals). - Positioned as the **largest hospital distributor in India**. - **Supplier & Product Network**: - Maintains relationships with **~83,000 SKUs from diverse healthcare manufacturers**. - Distributes **80,600+ SKUs** from over **2,700 manufacturers** in FY25, up from 68,900 SKUs from 2,000 in FY24. --- ### **Technology & Digital Innovation** Technology is at the core of Entero’s **scalable, efficient, and transparent operations**: - **Proprietary Integrated Platform**: - Enables real-time access to **pricing, inventory, order status, and promotional schemes**. - Supports **24/7 ordering, digital reconciliation, and AI-driven analytics**. - **Key Platforms**: - **Entero Direct**: B2B SaaS app for pharmacies, enabling **real-time inventory visibility, faster order processing, and improved fill rates**. - **Entero ERP & CRM**: Internally drives **performance management, sales planning, and customer retention**. - **Teqtic**: Cloud-based **data warehouse and analytics tool** providing micro-market insights. - **HealthEdge Program**: - Digital ecosystem for **independent retail chemists**, combining **Aayu Chemist app and Medcords platform**. - Offers **e-store creation, loyalty programs, cashback offers, and integrations (e.g., Paytm)** to improve profitability and digital engagement. --- ### **Growth Strategy: Organic + Inorganic Expansion** Entero’s ambitious growth is driven by **three pillars**: #### 1. **Organic Growth** - Targets 1.5x–2x industry growth rate (~30%+ YoY). - Expands in **Tier 2 and Tier 3 cities** through a **cluster-led branch expansion model**. - Focuses on **wallet share increase**, especially with hospital customers (private tertiary care, multi-specialty hospitals). #### 2. **Strategic Acquisitions (Inorganic Growth)** - Has completed **50+ acquisitions**—the **highest in the sector**—achieving the fastest operational scale-up. - Acquisitions in FY25 added **₹792 crore in annualized revenue (ARR)**; six new deals expected to add **₹400+ crore ARR** in FY26. - Target criteria: strategic fit in **new geographies, high-margin product adjacencies, capability enhancement**. - Acquired businesses typically acquired at **single-digit EV/EBITDA multiples**. - Post-acquisition integration boosts **acquired entity revenues by 60–88%** (e.g., Vasavi Medicare, R.S.M Pharma). - **Ownership structure**: Often acquires 70–80% stakes, retaining promoters to drive growth. #### 3. **Operational Excellence** - Investing in **master data management, automation, inter-warehouse transfers**, and **hub-and-spoke distribution model** for capital efficiency. - Aiming to reduce **working capital cycle to 60 days**. --- ### **Expansion into High-Growth Adjacent Segments** Entero is actively diversifying into **value-accretive, high-margin categories**: - **MedTech Distribution**: - Entering the **$13 billion Indian MedTech market**, focusing on **diagnostics, cardiology/orthopedic devices, and consumables**. - Expected to generate **₹1,000+ crore in annualized revenue** post-integration. - Higher distributor margins; expected to **lift gross margin by 70–90 bps and EBITDA margin by 50–75 bps** (pro forma, based on FY25 targets). - Acquires companies with **established distribution networks and hospital relationships**. - **Trade Generics & Specialty Pharma**: - Enters **higher-growth, margin-accretive generics**. - Expanding private-label portfolio under **Entero Surgicals**, including **nebulizers, gloves, mobility aids, and homecare devices**. - **Private Label & In-House Brands**: - Offers private label **medical devices, surgical consumables, and hygiene products**. --- ### **Financial Performance & Outlook** - **FY25 (2024–25)**: - Revenue: **₹5,096 crore** (+30% YoY). - EBITDA: **₹172 crore** (+53% YoY) → EBITDA margin improved to **3.4%** (from 2.9% in FY24). - PAT: **₹107 crore** (+170% YoY). - Positive operating cash flow. - **FY26 Outlook**: - Target **>30% revenue growth**, with **>4% full-year EBITDA margin**. - Acquisition pipeline supports **₹500 crore ARR inorganic contribution**. - **Q1 FY26 inorganic revenue: ₹230 crore** (up from ₹218 crore YoY). --- ### **Summary: Why Entero Stands Out** | Strength | Details | |--------|---------| | **Market Leadership** | Top 3 by revenue, largest hospital network, fastest scale-up via 50+ acquisitions. | | **Integrated Model** | Combines demand generation + fulfillment—rare in the industry. | | **Digital Core** | Proprietary tech stack (Entero Direct, HealthEdge) enables real-time insights and efficiency. | | **High-Growth Adjacencies** | MedTech, trade generics, and private labels improve margins. | | **Strong Financial Trajectory** | 30%+ revenue growth, margin expansion, positive cash flow. | | **Consolidation Leader** | Best-in-class M&A playbook, proven integration, and scalable platform. |